Evidence map›Paper›PMID 29985945›Full record

ArticlePloS one2018

Inhibition of ferrochelatase impairs vascular eNOS/NO and sGC/cGMP signaling.

Bin Zhang, Norah Alruwaili, Sharath Kandhi, Wensheng Deng, An Huang, Michael S Wolin, Dong Sun

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Ferrochelatase regulates retinal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bin ZhangDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
Norah AlruwailiDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
Sharath KandhiDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
Wensheng DengDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
An HuangDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
Michael S WolinDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.
Dong SunDepartments of Physiology, New York Medical College, Valhalla, New York, United States of America.ORCID 0000-0003-4845-2180
New York Medical College · US

Funding

Ferrochelatase & guanylate cyclase regulation in vascular dysfunctionR01HL129797 · NHLBI · NEW YORK MEDICAL COLLEGE · PI SUN, DONG, WOLIN, MICHAEL S · 2016 to 2019
$1.6M
ecSOD derived peroxide in pulmonary adaptation to hypoxiaR01HL115124 · NHLBI · NEW YORK MEDICAL COLLEGE · PI WOLIN, MICHAEL S · 2013 to 2016
$1.6M
NHLBI NIH HHS R01 HL115124NHLBI NIH HHS R01 HL129797
6 · The paper itself

Abstract

Ferrochelatase (FECH) is an enzyme necessary for heme synthesis, which is essential for maintaining normal functions of endothelial nitric oxide synthase (eNOS) and soluble guanylyl cyclase (sGC). We tested the hypothesis that inhibition of vascular FECH to attenuate heme synthesis downregulates eNOS and sGC expression, resulting in impaired NO/cGMP-dependent relaxation. To this end, isolated bovine coronary arteries (BCAs) were in vitro incubated without (as controls) or with N-methyl protoporphyrin (NMPP; 10(-5)-10(-7)M; a selective FECH antagonist) for 24 and 72 hours respectively. Tissue FECH activity, heme, nitrite/NO and superoxide levels were sequentially measured. Protein expression of FECH, eNOS and sGC was detected by western blot analysis. Vascular responses to various vasoactive agents were evaluated via isometric tension studies. Treatment of BCAs with NMPP initiated a time- and dose-dependent attenuation of FECH activity without changes in its protein expression, followed by significant reduction in the heme level. Moreover, ACh-induced relaxation and ACh-stimulated release of NO were significant reduced, associated with suppression of eNOS protein expression in NMPP-treated groups. Decreased relaxation to NO donor spermine-NONOate reached the statistical significance in BCAs incubated with NMPP for 72 hours, concomitantly with downregulation of sGCβ1 expression that was independent of heat shock protein 90 (HSP90), nor did it significantly affect BCA relaxation caused by BAY 58-2667 that activates sGC in the heme-deficiency. Neither vascular responses to non-NO/sGC-mediators nor production of superoxide was affected by NMPP-treatment. In conclusion, deletion of vascular heme production via inhibiting FECH elicits downregulation of eNOS and sGC expression, leading to an impaired NO-mediated relaxation in an oxidative stress-independent manner.

Indexed as

AcetylcholineAnimalsCattleCoronary VesselsCyclic GMPDose-Response Relationship, DrugFerrochelataseHSP90 Heat-Shock ProteinsNitric OxideNitric Oxide Synthase Type IIIProtoporphyrinsSignal TransductionSoluble Guanylyl CyclaseVasodilationVasodilator AgentsAcetylcholineCyclic GMPFerrochelataseHSP90 Heat-Shock ProteinsNitric OxideNitric Oxide Synthase Type IIIN-methylprotoporphyrin IXProtoporphyrinsSoluble Guanylyl CyclaseVasodilator Agents

Identifiers

PMID29985945
PMCPMC6037352
OpenAlexW2872967924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.